Actively Recruiting
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Led by Susan Chang · Updated on 2026-04-29
300
Participants Needed
1
Research Sites
524 weeks
Total Duration
On this page
Sponsors
S
Susan Chang
Lead Sponsor
G
GE Healthcare
Collaborating Sponsor
AI-Summary
What this Trial Is About
This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.
CONDITIONS
Official Title
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For patients in cohort 1: histologically proven lower grade glioma who are being followed with surveillance scans
- For patients in cohort 2: histologically proven glioma who are scheduled for treatment due to suspected residual or recurrent tumor
- Patients with a life expectancy > 12 weeks
- Patients must have a Karnofsky performance status of >= 60
- Patients must have adequate renal function (creatinine < 1.5 mg/dL) before imaging, tested within 60 days prior to hyperpolarized imaging scan
- Patients must not have any significant medical illnesses that cannot be controlled with therapy or that would compromise participation or obscure toxicity evaluation
- Patients must not have New York Heart Association (NYHA) grade II or greater congestive heart failure
- Patients must not have history of myocardial infarction or unstable angina within 12 months prior to enrollment
- Patients must sign informed consent and authorization for release of protected health information
- Patients may not be known to be HIV-positive; HIV testing not required
- Patients must not have a history of other cancers except non-melanoma skin cancer or carcinoma in-situ of the cervix unless in complete remission and off therapy for at least 3 years
- Patients must not be pregnant or breastfeeding
- Women of childbearing potential must have a negative pregnancy test within 14 days of imaging and use effective contraception; men must use effective contraception if of childbearing potential
You will not qualify if you...
- Subjects unable to comply with study and follow-up procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
W
Wendy Ma
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here